Utama › Penyakit Crohn › Connecticut
Kajian klinikal Penyakit Crohn di Connecticut
14 kajian untuk Penyakit Crohn sedang mencari peserta di lokasi di Connecticut.
Bandar di Connecticut
Teks kajian rasmi (Bahasa Inggeris)
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- Connecticut Clinical Research Institute ( Site 0297), Bristol
Mengambil pesertaFasa 3
Semua umur · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06651281A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Yale University School of Medicine-Digestive Disease ( Site 5019), New Haven
Mengambil pesertaFasa 3
Umur 16 hingga 80 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06430801Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Danbury Hospital, Western Connecticut Health Network /ID# 265556, Danbury
- Yale University School of Medicine /ID# 266786, New Haven
Mengambil pesertaFasa 2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06548542A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Medical Research Center of Connecticut, Hamden
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07499232Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Smilow Cancer Center/Yale-New Haven Hospital, New Haven
- Yale University, New Haven
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT03816345An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Yale University Digestive Disease-Site Number: 8400108, New Haven
Mengambil pesertaFasa 3
Umur 16 hingga 80 · Semua jantina · Dikemas kini 23 Sep 2026 · NCT07184931A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Connecticut Children's Medical Center, Hartford
Mengambil pesertaFasa 3
Umur 2 hingga 19 · Semua jantina · Dikemas kini 22 Sep 2026 · NCT04844606A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- Medical Research Center of Connecticut, LLC, Hamden
Mengambil pesertaFasa 4
Umur 18 hingga 70 · Semua jantina · Dikemas kini 9 Sep 2026 · NCT06045754A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Connecticut Children's Medical Center, Hartford
Mengambil pesertaFasa 3
Umur 2 hingga 17 · Semua jantina · Dikemas kini 24 Ogo 2026 · NCT05509777Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
- Yale University, New Haven
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Ogo 2026 · NCT05230173Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- Yale University School of Medicine, New Haven
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Ogo 2026 · NCT07237516Assessment and Educational Intervention to Reduce Ultra-processed Food Consumption in Pediatric Patients With IBD
- Connecticut Children's Medical Center, Hartford
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 10 hingga 21 · Semua jantina · Dikemas kini 16 Jul 2026 · NCT07224113Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- Connecticut Children's Medical Center - Hartford /ID# 262256, Hartford
Mengambil pesertaFasa 3
Umur 2 hingga 17 · Semua jantina · Dikemas kini 24 Jun 2026 · NCT06332534Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Connecticut Children's Medical Center, Hartford
Mengambil pesertaFasa 4
Umur 6 hingga 17 · Semua jantina · Dikemas kini 27 Mei 2026 · NCT05781152Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.